Heron Therapeutics Inc
AXD2
Company Profile
Business description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Contact
100 Regency Forect Drive
Suite 300
CaryNC27518
USAT: +1 858 251-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,831.80 | 37.40 | 0.43% |
| CAC 40 | 7,835.31 | 129.20 | -1.62% |
| DAX 40 | 24,939.35 | 259.84 | -1.03% |
| Dow JONES (US) | 50,926.56 | 20.51 | 0.04% |
| FTSE 100 | 10,428.27 | 177.73 | -1.68% |
| HKSE | 23,969.30 | 643.97 | -2.62% |
| NASDAQ | 26,871.60 | 10.53 | 0.04% |
| Nikkei 225 | 68,326.72 | 630.00 | -0.91% |
| NZX 50 Index | 13,664.70 | 145.81 | -1.06% |
| S&P 500 | 7,666.45 | 14.91 | 0.19% |
| S&P/ASX 200 | 8,656.70 | 42.30 | 0.49% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |